EcoDrugPlus

Dna (Cytosine-5-)-Methyltransferase 1

Ensembl ID : ENSHHUG00000043023
Gene Symbol: DNMT1
1 Cross references
71 Possible Orthologues:

Dna Topoisomerase I

Ensembl ID : ENSHHUG00000006775
Gene Symbol: TOP1
1 Cross references
198 Possible Orthologues:

Dna Topoisomerase Ii Alpha

Ensembl ID : ENSHHUG00000041153
Gene Symbol: TOP2A
1 Cross references
209 Possible Orthologues:

Dna Topoisomerase Ii Beta

Ensembl ID : ENSHHUG00000036340
Gene Symbol: TOP2B
1 Cross references
201 Possible Orthologues:

Dna Topoisomerase Ii Beta

Ensembl ID : ENSHHUG00000030126
Gene Symbol: TOP2B
2 Cross references
201 Possible Orthologues:

Dna Topoisomerase Ia

Ensembl ID : ENSHHUG00000028821
Gene Symbol: TOP1A
1 Cross references
201 Possible Orthologues:

Dna Topoisomerase Ia

Ensembl ID : ENSHHUG00000039127
Gene Symbol: TOP1A
1 Cross references
201 Possible Orthologues:

Emap Like 4

Ensembl ID : ENSHHUG00000038657
Gene Symbol: EML4
2 Cross references
201 Possible Orthologues:

Emap Like 4

Ensembl ID : ENSHHUG00000035368
Gene Symbol: EML4
1 Cross references
198 Possible Orthologues:

Eph Receptor A3

Ensembl ID : ENSHHUG00000026553
Gene Symbol: EPHA3
1 Cross references
158 Possible Orthologues:

F2r Like Thrombin Or Trypsin Receptor 3

Ensembl ID : ENSHHUG00000001265
Gene Symbol: F2RL3
1 Cross references
189 Possible Orthologues:

F2r Like Thrombin Or Trypsin Receptor 3

Ensembl ID : ENSHHUG00000049870
Gene Symbol: F2RL3
1 Cross references
189 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).